Single-dose immunization with virus replicon particles confers rapid robust protection against Rift Valley fever virus challenge

Journal of Virology

Volumn 86, Issue 8, 2012, Pages 4204-4212

  Dodd, Kimberly A ^a,b   Bird, Brian H ^a   Metcalfe, Maureen G ^a   Nichol, Stuart T ^a   Albariño, César G ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS REPLICON PARTICLE VACCINE; VIRUS VACCINE;

ACTIVE IMMUNIZATION; ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE EXPRESSION REGULATION; INFECTION RESISTANCE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; REPLICON; RIFT VALLEY FEVER; SINGLE DRUG DOSE; VIRUS PARTICLE; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE ORDER; IMMUNOGLOBULIN G; MICE; MICE, INBRED C57BL; RIFT VALLEY FEVER; RIFT VALLEY FEVER VIRUS; SURVIVAL ANALYSIS; VIRAL VACCINES; VIRION; VIRUS REPLICATION;

ANIMALIA; MUS; RIFT VALLEY FEVER VIRUS;

EID: 84861385641     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.07104-11     Document Type: Article

References (41)

1. Barnett SW, et al. 2010. Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant. J. Virol. 84:5975-5985.
2. Bhardwaj N, Heise MT, Ross TM. 2010. Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing gn protects mice against Rift Valley fever virus. PLoS Negl. Trop. Dis. 4:e725.
3. Billecocq A, et al. 2004. NSs protein of Rift Valley fever virus blocks interferon production by inhibiting host gene transcription. J. Virol. 78: 9798-9806.
4. Bird B, Ksiazek T, Nichol S. 2009. Rift Valley fever virus. J. Am. Vet. Med. Assoc. 234:883-893.
5. Bird BH, et al. 2008. Rift Valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals. J. Virol. 82:2681-2691.
6. Bird BH, Albariño CG, Nichol ST. 2007. Rift Valley fever virus lacking NSm proteins retains high virulence in vivo and may provide a model of human delayed onset neurologic disease. Virology 362:10-15.
7. Bird BH, et al. 2011. Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, non-teratogenic, and confers protection from viremia, pyrexia, and abortion following lethal challenge in adult and pregnant sheep. J. Virol. 85:12901-12909.
8. Botros B, et al. 2006. Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine. J. Med. Virol. 78:787-791.
9. Bouloy M, et al. 2001. Genetic evidence for an interferon-antagonistic function of Rift Valley fever virus nonstructural protein NSs. J. Virol. 75:1371-1377.
10. Chevalier V, Pépin M, Plée L, Lancelot R. 2010. Rift Valley fever-a threat for Europe? Euro Surveill. 15:19506.
11. de Boer SM, et al. 2010. Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge. Vaccine 28:2330-2339.
12. Defang GN, Khetawat D, Broder CC, Quinnan GV. 2010. Induction of neutralizing antibodies to Hendra and Nipah glycoproteins using a Venezuelan equine encephalitis virus in vivo expression system. Vaccine 29: 212-220.
13. Dungu B, et al. 2010. Evaluation of the efficacy and safety of the Rift Valley fever Clone 13 vaccine in sheep. Vaccine 28:4581-4587.
14. Elliott RM. 2009. Bunyaviruses and climate change. Clin. Microbiol. Infect. 15:510-517.
15. Elliott RM, Weber F. 2009. Bunyaviruses and the type I interferon system. Viruses 1:1003-1021.
16. Habjan M, et al. 2009. NSs protein of Rift Valley fever virus induces the specific degradation of the double-stranded RNA-dependent protein kinase. J. Virol. 83:4365-4375.
17. Hunter P, Erasmus BJ, Vorster JH. 2002. Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep. Onderstepoort J. Vet. Res. 69:95-98.
18. Ikegami T, et al. 2009. Dual functions of Rift Valley fever virus NSs protein: inhibition of host mRNA transcription and post-transcriptional downregulation of protein kinase PKR. Ann. N. Y. Acad. Sci. 1171(Suppl. 1):E75-E85.
19. Johnston RE, et al. 2005. Vaccination of macaques with SIV immunogens delivered by Venezuelan equine encephalitis virus replicon particle vectors followed by a mucosal challenge with SIVsmE660. Vaccine 23:4969-4979.
20. Katze MG, He Y, Gale M. 2002. Viruses and interferon: A fight for supremacy. Nat. Rev. Immunol. 2:675-687.
21. Kawai T, Akira S. 2008. Toll-like Receptor and RIG-1-like receptor signaling. Ann. N. Y. Acad. Sci. 1143:1-20.
22. Konopka JL, Thompson JM, Whitmore AC, Webb DL, Johnston RE. 2009. Acute infection with Venezuelan equine encephalitis virus replicon particles catalyzes a systemic antiviral state and protects from lethal virus challenge. J. Virol. 83:12432-12442.
23. Kortekaas J, et al. 2011. Creation of a non-spreading Rift Valley fever virus. J. Virol. 85:12622-12630.
24. Lagerqvist N, et al. 2009. Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley fever virus cDNA constructs. Virol. J. 6:6.
25. Le May N, et al. 2004. TFIIH transcription factor, a target for the Rift Valley hemorrhagic fever virus. Cell 116:541-550.
26. Le May N, et al. 2008. A SAP30 complex inhibits IFN-beta expression in Rift Valley fever virus infected cells. PLoS Pathog. 4:e13.
27. -/- mice induced by differentDNAvaccination regimens. Vaccine 28:2937-2944.
28. Lozach P-Y, et al. 2011. DC-SIGN as a receptor for phleboviruses. Cell Host Microbe 10:75-88.
29. Mandell RB, et al. 2010. A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge. Virology 397:187-198.
30. McElroy AK, Nichol ST. 2012. Rift Valley fever virus inhibits a proinflammatory response in experimentally infected human monocyte derived macrophages and a pro-inflammatory cytokine response may be associated with patient survival during natural infection. Virology 422:6-12.
31. Näslund J, et al. 2009. Vaccination with virus-like particles protects mice from lethal infection of Rift Valley fever virus. Virology 385:409-415.
32. National Research Council. 2011. Guide to the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
33. Niwa H, Yamamura K, Miyazaki J. 1991. Efficient selection for highexpression transfectants with a novel eukaryotic vector. Gene 108:193-199.
34. Schmaljohn CS, Nichol ST. 2007. Bunyaviridae, p 1741-1789. In Knipe DM et al (ed), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
35. Smith DR, et al. 2010. The pathogenesis of Rift Valley fever virus in the mouse model. Virology 407:256-267.
36. Suter R, et al. 2011. Immunogenic and replicative properties of classical swine fever virus replicon particles modified to induce IFN-α/β and carry foreign genes. Vaccine 29:1491-1503.
37. Swanepoel R, Coetzer JAW. 1994. Rift Valley fever, p 688-717. In Coetzer JAW, Thomson GR, and Tustin RC (ed), Infectious diseases of livestock with special reference to South Africa. Oxford University Press, Cape Town, South Africa.
38. Turell MJ, Wilson WC, Bennett KE. 2010. Potential for North American mosquitoes (Diptera: Culicidae) to transmit Rift Valley fever virus. J. Med. Entomol. 47:884-889.
39. Vialat P, Billecocq A, Kohl A, Bouloy M. 2000. The S segment of Rift Valley fever phlebovirus (Bunyaviridae) carries determinants for attenuation and virulence in mice. J. Virol. 74:1538-1543.
40. von Teichman B, et al. 2011. Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves. Vaccine 29:5771-5777.
41. Won S, Ikegami T, Peters CJ, Makino S. 2007. NSm protein of Rift Valley fever virus suppresses virus-induced apoptosis. J. Virol. 81:13335-13345.